Marie Camerota1, Jonathan M Davis2, Lynne M Dansereau3, Erica L Oliveira3, James F Padbury3, Barry M Lester4. 1. Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI; Department of Pediatrics, Women and Infants Hospital, Providence, RI. Electronic address: marie_camerota@brown.edu. 2. Department of Pediatrics, Tufts Children's Hospital and the Tufts Clinical and Translational Science Institute, Boston, MA. 3. Department of Pediatrics, Women and Infants Hospital, Providence, RI. 4. Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI; Department of Pediatrics, Women and Infants Hospital, Providence, RI.
Abstract
OBJECTIVE: To determine whether pharmacologic treatment for neonatal abstinence syndrome (NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor gene (OPRM1) and improvements in neonatal neurobehavior. STUDY DESIGN: Buccal swabs were collected from 37 neonates before and after morphine treatment for NAS. Genomic DNA was extracted, and DNAm was examined at 4 cytosine-phosphate-guanine (CpG) sites within the OPRM1 gene. Assessment with the NICU Network Neurobehavioral Scales (NNNS) was also performed before and after NAS treatment. Changes in DNAm (DNAmpost-tx - DNAmpre-tx) and NNNS summary scores (NNNSpost-tx - NNNSpre-tx) were then calculated. Path analysis was used to examine associations among pharmacologic treatment (length of treatment [LOT] and total dose of morphine), changes in DNAm, and changes in NNNS summary scores. RESULTS: DNAm was significantly decreased from pretreatment to post-treatment at 1 of 4 CpG sites within the OPRM1 gene. Neonates also demonstrated decreased excitability, hypertonia, lethargy, signs of stress and abstinence, and increased quality of movement and regulation from pretreatment to post-treatment. Longer LOT and higher morphine dose were associated with greater decreases in DNAm; greater decreases in DNAm were associated with greater decreases in excitability and hypertonia on the NNNS. CONCLUSIONS: Pharmacologic treatment of NAS is associated with decreased DNAm of the OPRM1 gene and improved neonatal neurobehavior. Epigenetic changes may play a role in these changes in neonatal neurobehavior.
OBJECTIVE: To determine whether pharmacologic treatment for neonatal abstinence syndrome (NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor gene (OPRM1) and improvements in neonatal neurobehavior. STUDY DESIGN: Buccal swabs were collected from 37 neonates before and after morphine treatment for NAS. Genomic DNA was extracted, and DNAm was examined at 4 cytosine-phosphate-guanine (CpG) sites within the OPRM1 gene. Assessment with the NICU Network Neurobehavioral Scales (NNNS) was also performed before and after NAS treatment. Changes in DNAm (DNAmpost-tx - DNAmpre-tx) and NNNS summary scores (NNNSpost-tx - NNNSpre-tx) were then calculated. Path analysis was used to examine associations among pharmacologic treatment (length of treatment [LOT] and total dose of morphine), changes in DNAm, and changes in NNNS summary scores. RESULTS: DNAm was significantly decreased from pretreatment to post-treatment at 1 of 4 CpG sites within the OPRM1 gene. Neonates also demonstrated decreased excitability, hypertonia, lethargy, signs of stress and abstinence, and increased quality of movement and regulation from pretreatment to post-treatment. Longer LOT and higher morphine dose were associated with greater decreases in DNAm; greater decreases in DNAm were associated with greater decreases in excitability and hypertonia on the NNNS. CONCLUSIONS: Pharmacologic treatment of NAS is associated with decreased DNAm of the OPRM1 gene and improved neonatal neurobehavior. Epigenetic changes may play a role in these changes in neonatal neurobehavior.
Authors: Barry M Lester; Edward Z Tronick; Linda LaGasse; Ronald Seifer; Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Linda L Wright; Vincent L Smeriglio; Jing Lu; Loretta P Finnegan; Penelope L Maza Journal: Pediatrics Date: 2002-12 Impact factor: 7.124
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Nicole A Heller; Beth A Logan; Deborah G Morrison; Jonathan A Paul; Mark S Brown; Marie J Hayes Journal: Dev Psychobiol Date: 2017-05-31 Impact factor: 3.038
Authors: Mara G Coyle; Amy L Salisbury; Barry M Lester; Hendrée E Jones; Hai Lin; Klaudia Graf-Rohrmeister; Gabriele Fischer Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Todd M Everson; Carmen J Marsit; T Michael O'Shea; Amber Burt; Karen Hermetz; Brian S Carter; Jennifer Helderman; Julie A Hofheimer; Elisabeth C McGowan; Charles R Neal; Steven L Pastyrnak; Lynne M Smith; Antoine Soliman; Sheri A DellaGrotta; Lynne M Dansereau; James F Padbury; Barry M Lester Journal: Sci Rep Date: 2019-04-19 Impact factor: 4.996
Authors: Leslie W Young; Zhuopei Hu; Robert D Annett; Abhik Das; Janell F Fuller; Rosemary D Higgins; Barry M Lester; Stephanie L Merhar; Alan E Simon; Songthip Ounpraseuth; P Brian Smith; Margaret M Crawford; Andrew M Atz; Lesley E Cottrell; Adam J Czynski; Sarah Newman; David A Paul; Pablo J Sánchez; Erin O Semmens; M Cody Smith; Christine B Turley; Bonny L Whalen; Brenda B Poindexter; Jessica N Snowden; Lori A Devlin Journal: Pediatrics Date: 2020-12-21 Impact factor: 7.124